logo image
search icon
Global Allogeneic Cell Therapy Manufacturing Market

Allogeneic Cell Therapy Manufacturing Market Size, Share & Trends Analysis Report By Product, By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, Commercial Scale Operations), By Region, And Segment Forecasts, 2023-2031

Report ID : 1194 | Published : 2024-05-21 | Pages: 170 | Format:

The Allogeneic Cell Therapy Manufacturing Market is expected to grow at a 15.0 % CAGR during the forecast period for 2023-2031.

Key Industry Insights & Findings from the Report:

  • The rise in chronic conditions such as cancer, autoimmune disorders, and cardiovascular diseases is a major driver.
  • The expanding use of allogeneic cell therapies across a wide range of medical conditions, including dermatological, neurological, and musculoskeletal disorders, is opening new market opportunities.
  • North America dominated the market and accounted for a global revenue share in 2023.
  • The technical complexity of cell therapy manufacturing, including the need for highly specialized equipment and skilled personnel, presents ongoing challenges.

Allogeneic Cell Therapy Manufacturing Market

Allogeneic cell therapies involve the transfer of cells from a donor to a patient. Allogeneic cells are collected from various sources, among which blood is the prominent source for allogeneic cells. The small volume of blood comprises many cells that quickly gets multiply.

The key factors driving the growth of the allogeneic cell therapy manufacturing market include the rising elderly population, high prevalence of chronic diseases, the growing demand for personalized treatments, increasing healthcare expenditure, rapid technological advancements in the healthcare sector. Many biopharma companies are collaborating to improve research and development activities in stem cell research, considering the need for allogeneic cell therapies. Likely to propel the growth opportunities for the allogeneic cell therapy manufacturing market in the forthcoming years. For instance, in September 2021, Adaptimmune Therapeutics (UK) partnered with Roche Group member, Genentech, to develop and market allogeneic cell therapies to treat multiple cancer indications.

However, the expensive manufacturing of allogeneic cell therapies and the risks associated with allogeneic cell therapies may hamper the market growth over the forecast period.

Market Segmentation

The allogeneic cell therapy manufacturing market is classified based on products, scale of operation, and region. By products, the market Induced pluripotent stem cells (iPSC), T-cells and Natural killer (NK) cells, Human pluripotent stem cells (hPSCs), Mesenchymal stem cells (MSC), β-cells, Neurons, Immortalized and engineered cell lines, and Tissue engineered product. The mesenchymal stem cells (MSCS) segment is expected to hold the maximum market share in the coming days due to the increasing R&D activities in stem cell therapies. The market is classified Preclinical Scale Operations, Clinical Scale Operations, and Commercial Scale Operations in terms of scale of operation.

Regionally, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is estimated to hold the maximum share of the market over the forecast years, followed by Europe owing to the growing patients of chronic diseases and surging R&D activities by key players to develop effective allogeneic cell therapies.

Recent Developments:

  • In February 2024, The University of Wisconsin Madison strategically partners with Waisman Biomanufacturing, a leading contract development and manufacturing organization (CDMO), to announce a strategic partnership with RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services. 

Competitive Landscape

Some Of The Key Players In The Allogeneic Cell Therapy Manufacturing Market:

  • Lonza Group,
  • KBI Biopharma, Inc.,
  • Waisman Biomanufacturing,
  • Cell and Gene Therapy Catapult,
  • Thermo Fisher Scientific, Inc.,
  • Merck KGaA,
  • Catalent Inc.,
  • Oxford Biomedica Plc,
  • Fujifilm Cellular Dynamics, Inc.,
  • Wuxi Apptec,
  • Charles River Laboratories International, Inc.,
  • The Discovery Labs LLC,
  • ABL, Inc.,
  • BioCentriq,
  • Commercializing Living Therapies

The Allogeneic Cell Therapy Manufacturing Market Report Scope

Report Attribute

Specifications

Market Size Value In 2022

USD 993.19 Million

Revenue Forecast In 2031

USD 3643.57 Million

Growth Rate CAGR

CAGR of 15.7 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Products, By Scale of Operations

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Lonza Group, KBI Biopharma, Inc., Waisman Biomanufacturing, Cell and Gene Therapy Catapult, Thermo Fisher Scientific, Inc., Merck KGaA, Catalent Inc., Oxford Biomedica Plc, Fujifilm Cellular Dynamics, Inc., Wuxi Apptec, Charles River Laboratories International, Inc., The Discovery Labs LLC, ABL, Inc., BioCentriq, Commercializing Living Therapies, and others.

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Allogeneic Cell Therapy Manufacturing Market Snapshot

Chapter 4. Global Allogeneic Cell Therapy Manufacturing Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Allogeneic Cell Therapy Clinical Trial/Pipeline Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Product, Estimates & Trend Analysis

5.1. By Products, & Market Share, 2019 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2030 for the following By Products:

5.2.1. Induced pluripotent stem cells (iPSC)

5.2.2. T-cells and Natural killer (NK) cells

5.2.3. Human pluripotent stem cells (hPSCs)

5.2.4. Mesenchymal stem cells (MSC)

5.2.5. β-cells

5.2.6. Neurons

5.2.7. Immortalized and engineered cell lines

5.2.8. Tissue engineered product

Chapter 6. Market Segmentation 2: By Scale of Operation Estimates & Trend Analysis

6.1. By Scale of Operation & Market Share, 2019& 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2030 for the following By Scale of Operation

6.2.1. Preclinical Scale Operations

6.2.2. Clinical Scale Operations

6.2.3. Commercial Scale Operations

Chapter 7. Allogeneic Cell Therapy Manufacturing Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) estimates and forecasts By Products, 2019-2030

7.1.2. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) estimates and forecasts By Scale of Operation, 2019-2030

7.1.3. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2019-2030

7.2. Europe

7.2.1. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, 2019-2030

7.2.2. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, 2019-2030

7.2.3. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2019-2030

7.3. Asia Pacific

7.3.1. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, 2019-2030

7.3.2. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, 2019-2030

7.3.3. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2019-2030

7.4. Latin America

7.4.1. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, (US$ Million) 2019-2030

7.4.2. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2019-2030

7.4.3. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2019-2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, (US$ Million) 2019-2030

7.5.2. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2019-2030

7.5.3. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2019-2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Lonza Group

8.2.2. KBI Biopharma, Inc.

8.2.3. Waisman Biomanufacturing

8.2.4. Cell and Gene Therapy Catapult

8.2.5. Thermo Fisher Scientific, Inc.

8.2.6. Merck KGaA

8.2.7. Catalent Inc.

8.2.8. Lonza Group

8.2.9. Oxford Biomedica Plc

8.2.10. Fujifilm Cellular Dynamics, Inc.

8.2.11. Wuxi Apptec

8.2.12. Charles River Laboratories International, Inc.

8.2.13. The Discovery Labs LLC

8.2.14. ABL, Inc.

8.2.15. BioCentriq

8.2.16. Commercializing Living Therapies

8.2.17. Other Prominent Players

Segmentation Of Allogeneic Cell Therapy Manufacturing Market

Global Allogeneic Cell Therapy Manufacturing Market, by Products, 2019-2030 (Value US$ Mn)

  • Induced pluripotent stem cells (iPSC)
  • T-cells and Natural killer (NK) cells
  • Human pluripotent stem cells (hPSCs)
  • Mesenchymal stem cells (MSC)
  • β-cells
  • Neurons
  • Immortalized and engineered cell lines
  • Tissue engineered product

Allogeneic Cell Therapy Manufacturing Market

Global Allogeneic Cell Therapy Manufacturing Market, by Scale of Operation, 2019-2030 (Value US$ Mn)

  • Preclinical Scale Operations
  • Clinical Scale Operations
  • Commercial Scale Operations

Global Allogeneic Cell Therapy Manufacturing Market, by Region, 2019-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

 

Competitive Landscape

  • Company Overview
  • Financial Performance
  • Key Development

Latest Strategic Developments

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

What is the Allogeneic Cell Therapy Manufacturing Market Growth?

Lonza Group, KBI Biopharma, Inc., Waisman Biomanufacturing, Cell and Gene Therapy Catapult, Thermo Fisher Scientific, Inc., Merck KGaA, Catalent Inc.,

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Biotechnology

Select Licence Type
$4500
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach